spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Phenomenex Introduces bioZen Series for Characterization of Biotherapeutics


Torrance, Calif. (April 16, 2018) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces bioZen – a new series of LC solutions for bioseparations in pharmaceutical, biopharmaceutical and academic research. The series encompasses both proven and entirely new media spanning two particle platforms – core-shell and thermally modified fully porous – along with new biocompatible titanium hardware. The initial bioZen product line features seven chemistries for the UHPLC and HPLC characterization of biotherapeutics such as monoclonal antibodies, antibody-drug conjugates and biosimilars. The offering includes specific LC chemistries for the analysis of aggregates and total mAb, intact mass and fragments, peptide mapping and quantitation and glycan mapping.

As an added benefit, all bioZen media, particle sizes and phases are available in Phenomenex’s new biocompatible titanium hardware, which minimizes secondary reactions, carryover and other recovery issues to provide better overall reproducibility than stainless steel hardware. It also minimizes the amount of time typically spent on column priming and does not interfere with protein or peptide integrity.

The bioZen thermally modified fully porous media is produced with Phenomenex’s proprietary post-synthetic thermal treatment process, which improves particle mechanical strength and inertness, providing significantly better peak shape and fewer unwanted secondary interactions than traditional LC media. The thermally modified media pairs well with high-efficiency bioZen Core-Shell Technology media which delivers increased resolution and sensitivity in shorter retention time windows. Both particle platforms undergo stringent QC testing to ensure consistent high quality, while all individual bioZen columns have QC protocols for specific biologic applications to confirm product performance and reproducibility.

"The bioZen series springs from our close work with customers who wanted a comprehensive product offering to cover all of their bioseparations needs," explains Simon Lomas, senior manager of global product marketing for Phenomenex. "This is an exciting and growing portfolio of novel particles, chemistries and biocompatible hardware, supported by our industry gurus, that all combine to help our customers overcome the many challenges associated with the characterization of biologics."

For more information, visit the bioZen web experience. http://biozenbioseparations.com/?utm_campaign=2018%20%20biozen%20launch&utm_source=ebr&utm_medium=advertising&utm_content=press_release



 

For more information regarding this article please contact:
Phenomenex Press Room
Tel: (310) 212-0555 (USA)
Email:
pressroom@phenomenex.com

 

 
Print this page
Send to a friend
   
spacer
News and Press Releases

Make a Clean Sweep with Teknomek’s New Anti-bacterial Cleaning Range

Teknomek has introduced a new range of anti-microbial cleaning tools designed to minimise risk in labs and cleanroom environments by reducing the potential for cross-contamination. The new products include brooms, deck scrubs, squeegees, scrapers, spades and buckets, all are available in a choice of five colours to support area segregation.
More info >>


White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

Industry Events

Clinical Trial Supply East coast 2018

16-17 October 2018, King of Prussia, PA

This unique event brings together leading pharma, device and biotech professionals from across the East Coast region, to collaboratively enhance the clinical supply chain. Over the two days, delegates and speakers will discuss how to select forecasting and planning technology, how to reduce waste in clinical trials supplies, how to choose your packaging strategy, but we will also discover all the new technologies that will disrupt your clinical trials supplies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement